Jubilant Ingrevia rises 5% as Rakesh Jhunjhunwala raises stake in firm

The shares of the firm were listed on the bourses on March 19 in the list of T Group of Securities

markets, promoter, companies, stake, stock market, sensex, correction, nifty, shares, growth, profit, economy, gain
SI Reporter New Delhi
2 min read Last Updated : Mar 23 2021 | 10:15 AM IST
Shares of Jubilant Ingrevia were locked in 5 per cent upper circuit limit at Rs 299 on the BSE, also its fresh 52-week high, in Tuesday's intra-day session after ace investor Rakesh Jhunjhunwala said that persons acting in his concert purchased an additional 3,04,009 equity shares in the company on March 19.

The persons acting in concert include Rekha Jhunjhunwala, Sushiladevi Gupta, Rare Enterprises and Rare Share & Stocks.

On February 15, Jhunjhunwala and persons acting his concert had been allotted 96,29,800 equity shares of Jubilant Ingrevia consequent to the composite scheme of arrangement of Jubilant Pharmova (formerly known as Jubilant Life Sciences). This had resulted in their total shareholding in the firm at 6.0458 per cent.

With the purchase of an additional stake in the firm on March 19, the total shareholding now stands at 6.2367 per cent, according to the exchange filing. READ HERE

The shares of the firm were listed on the bourses on March 19 in the list of T Group of Securities.

The company is the demerged pharma and life sciences business of Jubilant Lifesciences. The stock was listed on the bourses today at Rs 258.35 per share. Jubilant Lifesciences demerged Jubilant Ingrevia this year and later renamed itself Jubilant Pharmova.

Jubilant Ingrevia is a global integrated life science products and innovative solutions provider serving, pharmaceutical, nutrition, agrochemical, consumer and industrial customers. It offers a broad portfolio of high-quality ingredients that find application in a wide range of industries. Jubilant Ingrevia's portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Rakesh JhunjhunwalaBuzzing stocksMarketsJubilant Life SciencesNews

Next Story